UBS Group’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

UBS Group’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-110	Closed	-$286	–	10478
2024 Q1	$286	Buy	110 +108	+5,400%	+$301	﹤0.01%	8658
2023 Q4	$7	Hold	2	–	–	﹤0.01%	9144
2023 Q3	$10	Sell	2 -541	-100%	-$3.9K	﹤0.01%	9223
2023 Q2	$4.63K	Buy	543 +541	+27,050%	+$5.55K	﹤0.01%	7513
2023 Q1	$25	Sell	2 -5	-71%	-$66	﹤0.01%	9406
2022 Q4	$107	Hold	7	–	–	﹤0.01%	10398
2022 Q3	$0	Sell	7 -112	-94%	-$7.79K	﹤0.01%	11387
2022 Q2	$11K	Buy	119 +79	+198%	+$6.76K	﹤0.01%	7902
2022 Q1	$6K	Sell	40 -133	-77%	-$30.7K	﹤0.01%	9040
2021 Q4	$52K	Buy	173 +120	+226%	+$46K	﹤0.01%	6865
2021 Q3	$21K	Buy	53 +30	+130%	+$12.8K	﹤0.01%	7134
2021 Q2	$10K	Buy	+23	New	+$9.96K	﹤0.01%	8083

Other funds holding FNCH

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

UBS Group's FNCH Position: Q2 2024 in Review

UBS Group sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2024, closing a stake of 110 shares — an estimated $286 sold.

UBS Group first reported a position in FNCH in Q2 2021 and held it in 12 quarters. The position peaked at $52K in Q4 2021. 1 fund tracked by Wall St. Rank holds FNCH as of Q2 2024.

UBS Group reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
UBS Group sold 110 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2024, an estimated $286.
UBS Group first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q2 2021 and held it in 12 quarters.
UBS Group's Finch Therapeutics Group, Inc. Common Stock position peaked at $52K in Q4 2021.
1 fund tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2024.

Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.